Conference Description:

The role of the myeloid compartment in tumor resistance is becoming clear. As the landscape of targets continues to grow, the potential to target and manipulate myeloid cells to relieve immunosuppression has received increasing focus, due to its ability to relieve immunosuppression in the tumor microenvironment.

The 3rd Tumor Myeloid-Directed Therapies Summit captures this potential by uniting the industry leaders pioneering these myeloid activating therapies to share clinical progress while reviewing novel targets to activate macrophages, monocytes, dendritic cells and more.

Collaborate and learn from myeloid experts across industry and academia over 3 in-depth days of content, as they address the key bottlenecks limiting the efficacy and safety of these exciting treatments, including in vivo models, biomarkers of response, combination rationale, and myeloid biology to accelerate myeloid directed therapies

URLs:
Tickets: https://go.evvnt.com/1673214-0?pid=154Tickets: https://go.evvnt.com/1673214-2?pid=154
Prices:
Drug Developer Pricing Conference + 2 Workshops: USD 4946.00,
Drug Developer Pricing Conference Only: USD 2999.00,
Academic Pricing Conference + Workshop Day: USD 2946.00,
Academic Pricing Conference Only: USD 2599.00,
Service Provider Pricing Conference + Workshop Day: USD 6046.00,
Service Provider Pricing Conference Only: USD 3799.00

Speakers: Andrea Casazza, Director - Biology, Montis Biosciences, Benjamin Umiker, Principal Scientist, Jounce Therapeutics, Chan Whiting, Chief Development Officer, Actym Therapeutics Inc., Christine Bowman, Principal Investigator, Arcus Biosciences, Christophe Quéva, CSO, DEM Biopharma, Darren Ji, Co-Founder, Chief Executive Officer and Chairman Elpiscience Biopharmaceuticals Inc., Habib Hamidi, Senior Principal Scientist - Translational Bioinformatics, Oncology Biomarker Development Genentech Inc, Jamie Bates Director, Oncology, Gilead Sciences, Julia Schanin, Director of Pre-clinical Development, Allakos, Kamal Puri, Chief Scientific Officer, Oncoresponse, Kristin Tarbell, Senior Principal Scientist, Amgen Inc., Lisa Johnson, Director, Biomarker Sciences, Gilead Sciences, Loise Francisco, Senior Vice President, Biology , DEM Biopharma, Marc Chamberlain, Executive Medical Director, Pionyr Immunotherapeutics, Marco Campisi, Postdoctoral Research Fellow, Brigham and Women's - Dana Farber Cancer Institute, Michael Curran, Associate Professor, MD Anderson Cancer Center, Mina Seedhom, Senior Research Scientist , UMass Medical School, Ming Tang, Director of Computational Biology, Immunitas Therapeutics, Miriam Merad, Professor of Medicine and Director - Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, Nicolas Poirier, CEO, CSO,OSE, Immunotherapeutics, Nisit Khandelwal, Founder and Managing Director, iOmx Therapeutics AG, Peter Ellmark, Chief Science Officer, Alligator Bioscience AB, Shahin Aslam, Associate Principal Scientist, Merck and Co, Shruti Malu Director, Head of Discovery and Pharmacology, Immunitas Therapeutics, Stephane Peluso, CSO, Infinity Pharmaceuticals Inc., Sumiti Jain, Vice President, Head Of Research and Development, Inceptor Bio, Thomas Condamine, Vice President-Discovery and Translational Science, CARISMA Therapeutics Inc

Time: 09:00 to 17:00